Literature DB >> 22907068

Percutaneous posterior instrumentation followed by direct lateral interbody fusion for lumbar infectious spondylitis.

Kee-Yong Ha1, Young-Hoon Kim, Jun-Yeong Seo, Seung-Ho Bae.   

Abstract

STUDY
DESIGN: Retrospective study.
OBJECTIVES: To investigate the clinical feasibility and outcomes from direct lateral interbody fusion (DLIF) using autogenous bone grafts and percutaneous posterior instrumentation (PPI) for infectious spondylitis. SUMMARY OF BACKGROUND DATA: As one of the minimally invasive techniques, PPI has been attempted for various degenerative lumbar spine disorders combined with anterior lumbar interbody fusion or transforaminal lumbar interbody fusion. PPI has been played more roles recently as an internal fixation method for infectious spondylitis. However, the clinical outcomes of DLIF using an autogenous bone graft combined with PPI for infectious spondylitis have been rarely reported.
MATERIALS AND METHODS: Sixteen patients (mean age, 60.3 ± 18.8 y) who suffered from pyogenic spondylitis underwent single-stage DLIF using an autogenous iliac bone graft combined with PPI. Clinical and radiologic outcomes were evaluated by visual analog scale (VAS), Oswestry Disability Index (ODI), and eradication of primary disease. Radiologic outcomes were evaluated by changes of affected segmental lordosis and fusion status.
RESULTS: Bony fusion and eradication of primary disease were obtained in all patient except 1 case during the follow-up (mean, 31.3 ± 13.1 mo; range 14-46 mo). Preoperative VAS (7 ± 1.2) and ODI (61.3 ± 5.4) scores improved significantly at the last follow-up (VAS, 3.4 ± 1.5; ODI, 32.3 ± 15.4). C-reactive protein normalized at postoperative 20.1 ± 0.7 days (range, 15-28 d). Although height and lordosis in the affected segment were restored by surgery, all patients showed loss of the restored lordosis and height at the final follow-up. Loss of the restored lordosis and height were related to subsidence of the grafted bone.
CONCLUSIONS: Minimally invasive PPI followed by debridement and DLIF was a feasible surgical alternative in our consecutive 16 cases of pyogenic spondylitis. In most cases, however the subsidence of anteriorly grafted fusion was inevitable despite successful fusion and eradication of the primary lesion.

Entities:  

Mesh:

Year:  2013        PMID: 22907068     DOI: 10.1097/BSD.0b013e31826eaf56

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  5 in total

Review 1.  MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics.

Authors:  Jeff A Lehmen; Edward J Gerber
Journal:  Eur Spine J       Date:  2015-04-08       Impact factor: 3.134

2.  Skipping Pedicle Screw Insertion Into Infected Vertebra is a Risk Factor for Revision Surgery for Pyogenic Spondylitis in the Lower Thoracic and Lumbar Spine.

Authors:  Kosei Nagata; Takeshi Ando; Katsuyuki Sasaki; Daiki Urayama
Journal:  Int J Spine Surg       Date:  2020-12-29

3.  Extreme lateral interbody fusion and percutaneous pedicle screw fixation in the minimally invasive treatment of thoracic tuberculosis.

Authors:  Liang Deng; Yuan-Wei Zhang; Liang-Yu Xiong; Su-Li Zhang; Wen-Yan Ni; Qiang Xiao
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

4.  A New Treatment Algorithm That Incorporates Minimally Invasive Surgery for Pyogenic Spondylodiscitis in the Thoracic and Lumbar Spines: The Results of Its Clinical Application to a Series of 34 Patients.

Authors:  Yoichi Tani; Takanori Saito; Shinichiro Taniguchi; Masayuki Ishihara; Masaaki Paku; Takashi Adachi; Muneharu Ando; Yoshihisa Kotani
Journal:  Medicina (Kaunas)       Date:  2022-03-25       Impact factor: 2.948

5.  Minimally invasive far lateral debridement combined with posterior instrumentation for thoracic and lumbar tuberculosis without severe kyphosis.

Authors:  Wei Xiong; Bing Yu; Yao Zhang; Chunxiao Wang; Xiaojie Tang; Haifei Cao; Xibing Zhang; Qinyong Song; Fang Tan; Jiangwei Tan
Journal:  J Orthop Surg Res       Date:  2020-06-16       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.